Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02375451 · ClinicalTrials.gov registry record
Effect of Childhood Radioiodine Therapy on Salivary Function
A clinical trial of Thyroid Cancer and Xerostomia, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT02375451: Completed study of Thyroid Cancer and Xerostomia, sponsored by Boston Children's Hospital.
NCT02375451 is a study of Thyroid Cancer and Xerostomia that has completed, run by Boston Children's Hospital. The registered enrollment target is 70 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02375451, a study of Thyroid Cancer and Xerostomia, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Radioiodine (I-131) therapy for thyroid disease is known to decrease salivary function in adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The investigators goals are to answer this question by measuring salivary gland function before and after I-131 administration in children who receive radioiodine therapy at our hospital for thyroid disease.
Primary Outcome
sterile paper strip is used to measure saliva production (noninvasive testing)
Conditions Studied
Interventions
- OTHER Radioiodine
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-09 |
What the finished NCT02375451 record still lists
NCT02375451 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radioiodine is the first listed.
NCT02375451 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02375451 about?
NCT02375451 is a clinical study titled "Effect of Childhood Radioiodine Therapy on Salivary Function". Radioiodine (I-131) therapy for thyroid disease is known to decrease salivary function in adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The investigators goals are to answer this question by measuring salivary gland function before and after I-131 administra...
What is the current status of trial NCT02375451?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2014-09. Estimated completion is 2016-09.
What conditions does trial NCT02375451 study?
This clinical trial studies the following conditions: Thyroid Cancer, Xerostomia, Hyperthyroidism.
What interventions are being tested in trial NCT02375451?
The interventions under investigation include: Radioiodine (OTHER).
Who is sponsoring clinical trial NCT02375451?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02375451 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02375451's enrollment target sits among peer trials
70 20th of 46 higher than 25 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia